Levigress 250 Tablet contains Levetiracetam 250mg, an anticonvulsant medication primarily indicated for the treatment of epilepsy. It is used as adjunctive therapy in the management of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients aged one month and older. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. The drug is rapidly absorbed following oral administration, with peak plasma concentrations achieved within one hour, and it exhibits linear pharmacokinetics. Levigress 250 is generally well tolerated; common adverse effects include somnolence, dizziness, headache, and fatigue. It has a low potential for drug interactions due to minimal hepatic metabolism. Dosage should be individualized based on patient response and renal function, with gradual titration recommended to minimize adverse effects. Caution is advised in patients with renal impairment, and monitoring for behavioral changes or mood alterations is important during therapy. Levigress 250 Tablet should be used under strict medical supervision, and abrupt discontinuation should be avoided to prevent seizure exacerbation. This medication is a valuable option in comprehensive epilepsy management.